Pocket Program - CROI

Monday
March 4 Oral Sessions
Session 8 CROI 2013
11:00 28 Hormonal Contraception and Risk of HIV:
An Analysis of Data from the Microbicides
Development Programme Trial
Angela Crook* 1 , H Rees 2 , G Ramjee 3 , A Kamali 4 , S Kapiga 5 ,
M Chisembele 6 , M Gafos 1 , A Nunn 1 , R Hayes 7 , and S McCormack 1
1 MRC Clin Trials Unit, London, UK;; 2 Univ of the Witwatersrand,
Johannesburg, South Africa;; 3 MRC HIV Prevention Res Unit,
Durban, South Africa;; 4 MRC/UVRI Uganda Res Unit, Entebbe;;
5 Mwanza Intervention Trials Unit, Tanzania;; 6 Univ Teaching Hosp,
Lusaka, Zambia;; and 7 London Sch of Hygiene and Tropical Med, UK
11:15 29 Is Depot Medroxyprogesterone Acetate
Likely to Increase Infectivity in HIV-1 +
Women Receiving ART?
Summer Day* 1 , S Graham 1,2 , L Masese 1,2 , B Richardson 1,3 ,
J Kiarie 2 , W Jaoko 2 , B Estambale 2 , V Chohan 1,3 , J Overbaugh 3 ,
and S McClelland 1,2
1 Univ of Washington, Seattle, US;; 2 Inst of Tropical and Infectious
Diseases, Univ of Nairobi, Kenya;; and 3 Fred Hutchison Cancer Res
Ctr, Seattle, WA, US
11:30 30 Community-level Reductions in Estimated HIV
Incidence: HIV Prevention Trials Network 043,
Project Accept
Thomas Coates* 1 , S Eshleman 2 , S Chariyalertsak 3 , A Chingono 4 ,
G Gray 5 , J Mbwambo 6 , L Richter 7 , D Donnell 8 , E Piwowar-Manning 2 ,
M Kulich 9 , and the HPTN 043 Project Accept Study Team
1 Univ of California, Los Angeles, US;; 2 Johns Hopkins Univ Sch
of Med, Baltimore, MD, US;; 3 Chiang Mai Univ, Thailand;; 4 Univ
of Zimbabwe, Harare;; 5 Univ of the Witwatersrand, Soweto, South
Africa;; 6 Muhimbili Univ, Dar es Salaam, Tanzania;; 7 Human Sci Res
Council, Vulindlela, South Africa;; 8 Statistical Ctr for HIV/AIDS Res
and Prevention, Fred Hutchinson Cancer Res Ctr, Seattle, WA, US;;
and 9 Charles Univ, Prague, Czech Repulic
11:45 31 Which HIV Testing and Counseling Model
Works Best in African Outpatient Departments?
Results from the Strengthening HIV Test Access
and Treatment Uptake Study
AD McNaghten* 1 , A Schilsky Mneimneh 2 , T Farirai 3 , N Wamai 4 ,
M Ntiro 5 , J Sabatier 2 , N Makhunga-Ramfolo 6 , S Mwanasalli 7 ,
A Awor 4 , J Moore 2 , and Project STATUS Study Team
1 Emory Univ, Atlanta, GA, US;; 2 CDC, Atlanta, GA, US;; 3 CDC,
Pretoria, South Africa;; 4 CDC, Entebbe, Uganda;; 5 Ministry of Hlth
and Social Welfare, Dar es Salaam, Tanzania;; 6 Univ Res Co, LLC,
Pretoria, South Africa;; and 7 CDC, Dar es Salaam, Tanzania
12:00 32 Condom Efficacy by Consistency of Use
among MSM: US
Dawn Smith*, J Herbst, X Zhang, and C Rose
CDC, Atlanta, GA, US
k Monday, 10 am-12:15 pm; Ballroom 1-2
Session 9–Oral Abstracts
Advances in Hepatitis Therapy
Moderators:
Juergen Rockstroh, Univ of Bonn, Germany
Kimberly Workowski, Emory Univ Sch of Med, Atlanta, GA, US
10:00 33 Protective Effect of Hepatitis B Virus-active cART
against Primary Hepatitis B Virus Infection
M Heuft, G van den Berk, T Smissaert, W Blok, R Regez, L Dijksman,
and Kees Brinkman*
Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands
10:15 34 Increased Plasma and Intracellular Ribavirin
Concentrations Associated with Telaprevir Use
Kyle Hammond* 1 , L Jimmerson 1 , C MacBrayne 1 , M Ray 1 ,
L Bushman 1 , J Burton 1 , F Baouchi-Mokrane 2 , G Everson 1 ,
P Anderson 1 , and J Kiser 1
1 Univ of Colorado Denver, Aurora, US and 2 Denver Hlth Med Ctr,
CO, US
10:30 35 Pharmacokinetic Interactions of Darunavir/
ritonavir, Efavirenz, and Tenofovir with the
Hepatitis C Virus Protease Inhibitor Faldaprevir
in Healthy Volunteers
J Sabo 1 , Jens Kort* 1 , M Haschke 2 , C Ballow 3 , B Girlich 4 , U Feifel 5 ,
B Lang 6 , M Schobelock 1 , and M Elgadi 7
1 Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT,
US;; 2 Univ Hosp Basel, Switzerland;; 3 Buffalo Clin Res Ctr, NY,
US;; 4 Boehringer Ingelheim Schweiz GmbH, Basel, Switzerland;;
5 Boehringer Ingelheim Pharmaceuticals GmbH & Co KG,
Ingelheim, Germany;; 6 Boehringer Ingelheim Pharmaceuticals
GmbH & Co KG, Biberach, Germany;; and 7 Boehringer Ingelheim
Canada Ltd, Burlington
4 20th Conference on Retroviruses and Opportunistic Infections
10:45 36 High Early Virological Response with
Telaprevir-Pegylated-Interferon-Ribavirin
in Treatment-experienced Hepatitis C Virus
Genotype 1/HIV Co-infected Patients:
ANRS HC26 TelapreVIH Study
Laurent Cotte* 1 , J Braun 2 , C Lascoux-Combe 3,4 , C Vincent 2 ,
S Pol 3,5 , M-A Valentin 3,6 , K Lacombe 3 , D Nau 7 , J-P Aboulker 2 ,
J-M Molina 3,4 , and ANRS HC26 Study Group
1 INSERM U1052, Hospices Civils de Lyon, France;; 2 INSERM
SC10-US019, Villejuif, France;; 3 Assistance Publ Hosp de Paris,
France;; 4 Univ Paris VII Denis Diderot, Paris, France;; 5 Univ Paris
Descartes, Paris, France;; 6 INSERM UMR-S 943, Paris, France;;
and 7 Hosp Pellegrin, Bordeaux, France
11:00 37 ANRS-HC27 BocepreVIH Interim Analysis:
High Early Virologic Response with Boceprevir
+ Pegylated Interferon + Ribivirin in Hepatitis
C Virus/HIV Co-infected Patients with Previous
Failure to Pegylated Interferon + Ribivirin
Isabelle Poizot-Martin* 1 , E Bellissant 2 , L Piroth 3 , A Renault 2 ,
Y Quertainmont 4 , E Rosenthal 5 , L Alric 6 , D Guyader 2 , M Bourliere 7 ,
J-M Molina 8 , and ANRS-HC27 BOCEPREVIH Study Group
1 Hosp Ste Marguerite, Marseille, France;; 2 Hosp de Pontchaillou,
Rennes, France;; 3 Hosp du Bocage, Dijon, France;; 4 Hosp de
Kremlin-Bicetre, Paris, France;; 5 Hosp de LArchet, Nice, France;;
6 Hosp de Purpan, Toulouse, France;; 7 Hosp St-Joseph, Marseille,
France;; and 8 Hosp St-Louis, Paris, France
11:15 38 12 Weeks of ABT-450/Ritonavir, Non-nucleoside
Inhibitor and Ribavirin Achieved SVR24 in
>90% of Treatment-naïve Hepatitis C Virus GT1
Patients and 47% of Prior Non-responders
Eric Lawitz* 1 , D Cohen 2 , F Poordad 1 , K Kowdley 3 , G Everson 4 ,
B Freilich 5 , D Jensen 6 , M Heckaman 2 , T Pilot-Matias 2 , and B Bernstein 2
1 Alamo Med Res, San Antonio, TX, US;; 2 Abbott, Abbott Park, IL, US;;
3 Digestive Disease Inst, Virginia Mason Med Ctr, Seattle, WA, US;;
4 Univ of Colorado Denver and Univ of Colorado Hosp, Aurora, US;;
5 Kansas City Gastroenterology and Hepatology, MO, US;; and 6 Ctr
for Liver Diseases, Univ of Chicago Med Ctr, IL, US
11:30 39 Risk of Virologic Relapse in Hepatitis C Virus
GT1-infected Subjects after 8, 12, and 24 Weeks
of ABT-450/r+ABT-267+ABT-333+Ribavirin:
Identifying Optimal Treatment Duration
Martin King*, W Xie, L Larsen, D Cohen, T Podsadecki,
and B Bernstein
AbbVie, North Chicago, IL, US
11:45 40LB STARTVerso 4: High Rates of Early Virologic
Response in Hepatitis C Virus Genotype 1/HIV
Co-infected Patients Treated with Faldaprevir +
Pegylated Interferon and Ribavirin
Douglas Dieterich* 1 , V Soriano 2 , M Nelson 3 , J Rockstroh 4 ,
K Arasteh 5 , S Bhagani 6 , A Talal 7 , C Tural 8 , R Vinisko 9 , and J Kort 9
1 Mt Sinai Sch of Med, New York, NY, US;; 2 Hosp Carlos III, Madrid,
Spain;; 3 Chelsea and Westminster Hosp, London, UK;; 4 Univ of Bonn,
Germany;; 5 EPIMED, Vivantes Auguste-Viktoria Hosp, Berlin,
Germany;; 6 Royal Free Hosp, London, UK;; 7 State Univ of New York,
Buffalo, US;; 8 Hosp Univ Germans Trias i Pujol, Barcelona, Spain;;
and 9 Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT, US
12:00 41LB ELECTRON: 100% Suppression of Viral Load
through 4 Weeks Post-treatment for Sofosbuvir
+ Ledipasvir (GS-5885) + Ribavirin for 12 Weeks
in Treatment-naïve and -experienced Hepatitis C
Virus GT1 Patients
Edward Gane* 1 , R Hyland 2 , X Ding 2 , P Pang 2 ,
J McHutchison 2 , W Symonds 2 , and C Stedman 3
1 Auckland Clin Studies, New Zealand;; 2 Gilead Sci, Foster City, CA,
US;; and 3 Christchurch Hosp, New Zealand